The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
Few peptides in this book have an origin story as surprising as kisspeptin's. The gene was discovered in a cancer laboratory, named after a candy made in the same Pennsylvania town, and spent years as a metastasis suppressor curiosity before scientists realized it held the master switch for the entire human reproductive axis.
In 1996, Danny Welch's laboratory at the Pennsylvania State University College of Medicine in Hershey, Pennsylvania — the home of Hershey's Kisses chocolate — was studying metastasis suppressor genes in human melanoma. They isolated a cDNA from chromosome 6 that, when introduced into metastatic melanoma cell lines, dramatically suppressed the ability of those cells to form distant metastases. The gene was named KISS1, a lighthearted reference to the town's famous candy. The encoded protein was later called kisspeptin (and originally metastin). For several years, KISS1 research was primarily in oncology — a metastasis suppressor gene with interesting but incompletely understood mechanisms.
The reproductive significance emerged in 2001, when three research groups simultaneously identified kisspeptin as the endogenous ligand for GPR54 — an orphan G protein-coupled receptor that had been cloned in 1999 but whose natural activating ligand was unknown. Ohtaki et al., Kotani et al., and Muir et al. all published in 2001 establishing that kisspeptin peptides were potent, specific agonists at GPR54. At this point, GPR54 was still an orphan receptor without a known physiological role.
The critical breakthrough came in 2003 in one of the most significant neuroendocrinology papers of the decade: Seminara et al. (New England Journal of Medicine, 2003) and simultaneously de Roux et al. discovered that loss-of-function mutations in GPR54 (now renamed KISS1R) caused hypogonadotropic hypogonadism in both mice and humans — complete failure to enter puberty, absent pubertal development, and adult infertility. The pathway was not just present in the brain; it was obligatory for normal human reproduction. Conversely, gain-of-function mutations in KISS1 and KISS1R cause precocious puberty — triggering the reproductive axis too early. These human genetic findings established kisspeptin/KISS1R as the essential gatekeeper of puberty and a master regulator of adult reproductive function.
The following decade produced an explosion of research: the identification of KNDy neurons (kisspeptin/neurokinin B/dynorphin) as the GnRH pulse generator; the establishment of kisspeptin's roles in sex steroid feedback, seasonal reproduction, stress-mediated reproductive suppression, and metabolic signals to the reproductive axis; and the first clinical studies in humans demonstrating that exogenous kisspeptin reliably stimulates LH secretion and GnRH pulse frequency. The compound named after chocolate became one of the most pharmacologically important neuropeptides in reproductive endocrinology.
THE CENTRAL TENSION
Kisspeptin-10 sits at the apex of the HPG axis — the most upstream endogenous regulator of GnRH pulsatility ever identified, with grade A evidence that it stimulates LH, testosterone, and GnRH pulse frequency in healthy men, and clinical trial evidence across HH, hypothalamic amenorrhea, IVF triggering, and hypoactive sexual desire disorder. The community uses it primarily for PCT — specifically to address the hypothalamic level of HPG axis recovery that hCG (Leydig cell level) and SERMs (pituitary level) do not directly target. This PCT application has compelling mechanistic support and zero controlled human trial data. Community users are self-administering a potent hypothalamic neuropeptide that can produce either HPG stimulation or, if dosed incorrectly (too frequently), complete hypothalamic suppression equivalent to medical castration. The gap between pharmacological position and clinical evidence is wider than for almost any other community-used peptide in this book.
The community use of kisspeptin for post-cycle therapy represents the most pharmacologically sophisticated reasoning in the peptide PCT literature — and simultaneously one of the least evidence-supported specific applications.
Standard post-cycle therapy protocol (hCG + SERM) addresses HPG axis suppression at two of the three levels: hCG addresses the testicular (Leydig cell) level — it directly stimulates Leydig cells to resume testosterone production, bypassing the suppressed pituitary. SERMs (clomiphene, tamoxifen) address the pituitary level — they block pituitary estrogen receptor-mediated LH suppression and restore endogenous LH secretion. Neither hCG nor SERMs specifically address the hypothalamic level — the GnRH pulse generator. After a prolonged AAS cycle, the hypothalamic KNDy neuron network has been chronically suppressed by negative feedback from exogenous androgens. GnRH pulse frequency and amplitude are reduced. The pituitary becomes accustomed to minimal GnRH input. Standard PCT helps the pituitary resume LH secretion, but whether the hypothalamic GnRH pulse generator fully recovers on the same timeline as pituitary and Leydig cell function is not well-characterized. Clinically, many post-AAS users report prolonged 'HPG sluggishness' — low LH, low testosterone, poor energy, depressed mood — even after standard PCT. Kisspeptin addresses this hypothalamic gap directly: as a direct KISS1R agonist on GnRH neurons, it stimulates GnRH pulse generator activity independently of the endogenous KNDy neuron function, which may still be suppressed.
The theoretical framework for kisspeptin in PCT: (1) During AAS cycle: exogenous androgens suppress KNDy neuron kisspeptin release (via androgen and estrogen receptor-mediated inhibition of KISS1 gene expression and KNDy neuron activity). GnRH pulsatility suppressed. (2) Immediately post-cycle: androgen levels crash. But KNDy neurons take time to recover their endogenous kisspeptin production. The hypothalamic suppression may persist longer than peripheral testosterone clearance. (3) PCT role for kisspeptin: administer exogenous KP-10 in pulsatile fashion to directly activate KISS1R on GnRH neurons → restore GnRH pulse frequency → downstream LH/FSH recovery → testicular function recovery. This provides HPG axis restart from the top down — the most physiologically upstream possible approach. The analogy to hypothalamic amenorrhea recovery (where exogenous kisspeptin restores GnRH pulsatility during hypothalamic suppression) is the closest available clinical parallel.
Community kisspeptin PCT protocols vary widely and lack the standardization of the hCG/SERM protocol. The general principles that have emerged from community practice and mechanistic reasoning: (1) Pulsatile dosing is mandatory — single daily dose or twice daily with 8-12+ hour interval; never multiple doses within the same few hours. (2) SubQ injection preferred over IV (impractical in community context); shorter half-life means SubQ produces a burst of KISS1R activation followed by rapid clearance. (3) Typical doses cited in community: 25-75 mcg KP-10 SubQ per injection; 50 mcg being a common reference point. (4) Duration: 2-4 weeks, often as Phase 0 (pre-SERM phase) or alongside hCG. (5) Combination with gonadorelin (GnRH) or GnRH analogs: some practitioners combine kisspeptin with gonadorelin for parallel hypothalamic and pituitary-level stimulation; theoretical but unvalidated. The evidence grade for any of these protocols: Grade D-E. There is no clinical trial evaluating kisspeptin in the post-AAS PCT context.
The KISS1 gene encodes a 145-amino acid precursor protein. This precursor is proteolytically cleaved in different tissues to generate a family of C-terminal amidated bioactive kisspeptin fragments, all of which bind KISS1R with equal affinity: Kisspeptin-54 (KP-54, formerly metastin): 54 amino acids; the dominant circulating form; longest half-life (~28 minutes IV); most extensively studied in clinical trials. Kisspeptin-14 (KP-14): 14 amino acids. Kisspeptin-13 (KP-13): 13 amino acids. Kisspeptin-10 (KP-10): 10 amino acids; the minimal active fragment; shortest half-life (~4 minutes IV). All four share the C-terminal RF-NH₂ sequence (Arg-Phe-amide) that is required for KISS1R binding. The C-terminal amidation (the -NH₂ at the Phe terminus) is obligatory — non-amidated kisspeptin fragments cannot activate KISS1R. Kisspeptin-10 sequence: Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂. MW approximately 1302 Da.
Early animal studies (pre-2010) suggested that KP-54 was more potent than KP-10 in stimulating LH secretion. This appeared to reflect the longer half-life of KP-54 (slower clearance due to N-terminal domain providing some protease resistance) rather than differential receptor affinity. In vitro binding assays show equal KISS1R affinity for KP-10 and KP-54. In the pivotal George et al. 2011 JCEM study in healthy men, IV bolus KP-10 produced a 2.5x LH increase from baseline comparable to equimolar KP-54 doses — confirming equal in vivo potency on a molar basis. KP-10's shorter half-life (~4 minutes IV) means it is cleared more rapidly, making it more suitable for pulsatile protocols where precise timing of receptor activation and clearance matters. KP-54's longer half-life (~28 minutes IV) makes it more suitable for prolonged stimulation contexts (IVF triggers, clinical infusion studies). For community SubQ dosing, both forms have been used with similar outcomes.
THE KNDy NEURON CONCEPT — THE MOST IMPORTANT NEUROSCIENCE IN HPG AXIS BIOLOGY
KNDy neurons (so-named because they co-express three neuropeptides simultaneously: Kisspeptin, Neurokinin B, and Dynorphin) in the arcuate nucleus of the hypothalamus are now understood to be the GnRH pulse generator — the pacemaker of the entire reproductive axis. The tripartite co-expression creates an auto-regulatory system: Kisspeptin stimulates adjacent GnRH neurons (excitatory). Neurokinin B (NKB) acts on NKB receptors on KNDy neurons themselves — NKB is thought to be the 'ignition' signal that starts each GnRH pulse by synchronizing KNDy neuron firing. Dynorphin (an endogenous opioid) acts on kappa-opioid receptors to terminate each pulse — the 'brake' signal that ends the GnRH burst and resets the pulse generator. This KNDy tripartite pacemaker explains how the hypothalamus generates regular, rhythmic GnRH pulses (approximately every 60-90 minutes in the normal physiological state). Kisspeptin-10 administered exogenously bypasses the KNDy pacemaker function and directly activates KISS1R on GnRH neurons — providing the excitatory signal without requiring endogenous KNDy neuron activity. This is why kisspeptin can restore GnRH pulsatility even when KNDy neurons themselves are dysfunctional or suppressed (as in hypothalamic amenorrhea or post-AAS HPG suppression).
KISS1R (GPR54) is a Gq/11-coupled GPCR expressed primarily on GnRH neurons in the hypothalamus, as well as in the pituitary, testes (Leydig cells and seminiferous tubules), ovaries, and limbic brain regions. KP-10 binding to KISS1R → Gq/11 coupling → phospholipase C activation → IP3 generation → intracellular Ca²⁺ release → neuronal depolarization → GnRH secretion. The response to kisspeptin is characteristically large and sustained compared to most GnRH-activating signals: a single kisspeptin bolus produces a prolonged, multi-minute GnRH neuron firing event rather than a brief transient. This sustained activation profile produces the pronounced LH pulses observed clinically — the 2.5-fold LH increase documented by George et al. represents this exaggerated GnRH neuron response.
The downstream cascade from KISS1R activation: (1) GnRH neurons fire → GnRH released into portal circulation → anterior pituitary. (2) GnRH binds GnRH receptors on gonadotroph cells → LH and FSH synthesis and secretion. (3) LH → binds LHCGR on Leydig cells in the testes → cAMP/PKA → testosterone synthesis. (4) FSH → binds FSH receptors on Sertoli cells → spermatogenesis support. The entire cascade from KISS1R activation to testosterone elevation occurs within 30-90 minutes. The magnitude of LH response in clinical studies: approximately 2-2.5x baseline in healthy eugonadal men; potentially larger in severely hypogonadotropic individuals where the pituitary is primed with accumulated LH.
THE DESENSITIZATION PARADOX — CONTINUOUS KISSPEPTIN SUPPRESSES THE AXIS IT IS SUPPOSED TO RESTORE
This is the most dangerous clinical pharmacology principle in the kisspeptin chapter, and the one most frequently misunderstood in community use. KISS1R undergoes agonist-induced desensitization — a universal GPCR phenomenon where sustained receptor occupancy leads to receptor internalization, uncoupling from G proteins, and eventual receptor downregulation. For kisspeptin, the consequence is: continuous or too-frequent kisspeptin administration → KISS1R desensitization → GnRH neurons become unresponsive to kisspeptin → GnRH pulse generation ceases → LH and FSH drop → gonadal suppression. This is precisely the mechanism by which continuous GnRH agonists (like leuprolide) produce medical castration — by continuous overstimulation of GnRH receptors until they desensitize completely. Continuous kisspeptin has the same effect on KISS1R that continuous GnRH has on GnRH receptors: paradoxical suppression. This is not a theoretical concern — it has been demonstrated in animal studies and is the mechanistic basis for the 'kisspeptin antagonist therapy for estrogen-dependent cancers' research program. The clinical requirement: pulsatile administration. Each kisspeptin dose must be given as a discrete bolus, with adequate interval for KISS1R resensitization (minimum 60-90 minutes; optimal likely 2-4+ hours), before the next dose. The community protocol of 1-2 SubQ injections per day, spaced 8-12+ hours apart, is consistent with maintaining KISS1R sensitivity. Administering kisspeptin multiple times per day with short intervals risks axis suppression rather than stimulation.
Beyond hypothalamic GnRH activation, KISS1R is expressed in limbic and paralimbic brain regions including the amygdala, hippocampus, and anterior cingulate cortex. These regions coordinate sexual behavior, emotional processing, bonding, and approach motivation. The Comninos et al. 2017 J Clin Invest study is the key human evidence: 29 healthy men underwent fMRI scanning while viewing sexual, bonding-related, and neutral images, receiving kisspeptin or placebo infusion in a double-blind crossover design. Results: kisspeptin significantly enhanced limbic brain activation specifically in response to sexual and couple-bonding stimuli — not neutral stimuli. The amygdala, hippocampus, and related limbic structures showed increased BOLD signal. Furthermore, the magnitude of this enhancement correlated with psychometric measures of reward, drive, and reduced sexual aversion. Kisspeptin did not produce non-specific global brain activation — it selectively amplified limbic responses to reproductively relevant stimuli. This suggests kisspeptin integrates reproductive hormone signaling with behavioral motivation in a way that coordinates the physiological and behavioral aspects of reproduction simultaneously — stimulating both the hormonal axis and the behavioral motivation for reproduction.
Kisspeptin-10 has been evaluated in more human clinical studies than almost any other community-used peptide in this book. The evidence is condition-specific, concentrated in reproductive endocrinology, and genuinely strong within those specific indications.
George JT et al. (2011, Journal of Clinical Endocrinology and Metabolism): KP-10 is a potent stimulator of LH and increases GnRH pulse frequency in men. IV bolus KP-10 produced a 2.5-fold increase in serum LH from baseline — comparable to equimolar KP-54. KP-10 infusion over 22.5 hours increased GnRH pulse frequency without desensitization at the study dose and infusion rate. Both effects were abolished by pre-treatment with a GnRH antagonist, confirming the effect is mediated through hypothalamic GnRH neurons rather than directly on the pituitary. This is the foundational human pharmacodynamics study for KP-10 specifically in men.
In idiopathic hypogonadotropic hypogonadism (IHH) — a condition characterized by absent or severely reduced GnRH-driven LH/FSH secretion — kisspeptin serves a dual role: diagnostic probe and potential therapeutic. As a diagnostic probe: the 'kisspeptin-10 challenge test' distinguishes patients with intact GnRH neurons (who respond to kisspeptin with LH secretion) from those without functional GnRH neurons (who do not respond). This mechanistic differentiation cannot be achieved with standard hormone panel testing — a positive kisspeptin response confirms functional GnRH neurons capable of responding to upstream signaling restoration, which has significant implications for treatment selection. Therapeutically: in men with functional HH (intact GnRH neurons, deficient kisspeptin signaling upstream), kisspeptin administration can restore LH pulsatility and testosterone secretion.
Jayasena CN, Dhillo WS, and colleagues (Imperial College London) have conducted multiple randomized controlled trials of kisspeptin in women with hypothalamic amenorrhea (HA) — a condition where excessive exercise, stress, or low body weight suppresses kisspeptin neuron activity and collapses GnRH pulsatility, causing loss of menstrual cycles. Key findings: pulsatile kisspeptin administration (subcutaneous pulses every 90 minutes) restores LH pulsatility and leads to follicle development in women with HA. One RCT (Jayasena 2014) showed pulsatile KP-54 produced ovulation in a subset of HA women; another showed pulsatile KP-10 stimulated LH pulsatility comparably. This is Grade A evidence that exogenous kisspeptin can restore the GnRH pulse generator when it is suppressed by physiological stressors — the closest analogue available for the post-AAS hypothalamic suppression context.
Conventional IVF protocols use hCG to trigger final oocyte maturation, but hCG's long half-life significantly increases ovarian hyperstimulation syndrome (OHSS) risk. Kisspeptin-54 as an IVF trigger has been evaluated in multiple RCTs by the Imperial College London group. The pivotal trial (Abbara 2015, Clinical Endocrinology): KP-54 trigger in women at high risk of OHSS achieved comparable oocyte retrieval to hCG while dramatically reducing OHSS incidence. Subsequent studies refined dosing and confirmed that kisspeptin-triggered IVF cycles produce viable pregnancies at rates comparable to hCG. Kisspeptin-54 as an IVF trigger works by briefly stimulating a LH surge through hypothalamic-pituitary pathways — the short half-life produces a transient LH peak that triggers oocyte maturation without the sustained LHCGR stimulation that causes OHSS. Grade A evidence for IVF triggering in the appropriate population.
Two randomized clinical trials published in JAMA Network Open directly tested kisspeptin for hypoactive sexual desire disorder (HSDD). Thurston L et al. (2022): Women with HSDD received kisspeptin infusion or placebo in a crossover design; kisspeptin significantly increased sexual attraction to the subject's partner as measured by neuroimaging and psychometric scales. Mills EG et al. (2023): Men with HSDD received kisspeptin infusion or placebo; kisspeptin significantly increased penile tumescence in response to erotic stimuli and enhanced sexual brain processing by fMRI. Both trials provide controlled evidence that kisspeptin has direct behavioral effects on sexual motivation beyond its hormonal actions — specifically through limbic brain KISS1R activation, not just testosterone elevation. Grade B (Phase 2 RCTs; results compelling; replication needed; infusion protocol not a community-replicable dosing method).
Indication
Grade
Key Evidence
Status
LH stimulation in healthy men
A
George 2011 JCEM; 2.5x LH increase; GnRH pulse frequency increase; abolished by GnRH antagonist
Foundational human pharmacodynamics
HH diagnostic probe
A
KP-10 challenge test distinguishes GnRH-intact from GnRH-absent HH; multiple clinical centers
Clinical tool; not yet standardized
Hypothalamic amenorrhea treatment
A
Jayasena et al. multiple RCTs; pulsatile KP restores LH pulsatility; ovulation induction
Strongest therapeutic evidence
IVF oocyte triggering (high OHSS risk)
A
Abbara 2015 and follow-up RCTs; comparable retrieval; dramatically reduced OHSS
Active clinical development; not yet FDA-approved for this indication
HSDD (women)
B
Thurston 2022 JAMA Netw Open; increased sexual attraction to partner
Phase 2 RCT; replication needed
HSDD (men)
B
Mills 2023 JAMA Netw Open; improved penile tumescence; enhanced sexual brain processing
Phase 2 RCT; replication needed
Post-AAS PCT (HPG axis restoration)
D-E
No controlled human trial; mechanistically compelling; community use experimental
Community use only; not studied
The C4 audit for kisspeptin yields genuinely interesting findings — this is not a compound with incidental behavioral effects but one with documented, fMRI-confirmed effects on limbic brain processing specifically related to sexual motivation and emotional bonding.
KISS1R expression in the brain is not limited to hypothalamic GnRH neurons. Significant KISS1R expression has been identified in the amygdala, hippocampus, anterior cingulate cortex, and other limbic and paralimbic structures. These regions coordinate sexual arousal, emotional memory, social bonding, and approach vs. avoidance motivation. Kisspeptin expression in the amygdala suggests a role in integrating olfactory and chemosensory signals (important for sexual partner recognition) with reproductive hormone secretion — a functional link documented in rodent studies where kisspeptin in the medial amygdala modulates reproductive hormone secretion in response to social stimuli.
Comninos AN et al. (Journal of Clinical Investigation, 2017): a prospective, double-blind, placebo-controlled crossover trial in 29 healthy men. Subjects received IV kisspeptin or placebo infusion while undergoing fMRI scanning and viewing sexual images, couple-bonding images, and neutral images. Key results: kisspeptin significantly enhanced BOLD signal in the limbic system (amygdala, hippocampus, anterior cingulate cortex) specifically in response to sexual and couple-bonding stimuli — not to neutral stimuli. The enhancement was stimulus-selective: kisspeptin amplified responses to reproductively relevant stimuli rather than producing non-specific brain activation. Enhancement of limbic activity correlated with psychometric measures of reward sensitivity, drive, and reduced sexual aversion. These correlations provide functional significance — the brain changes predicted behavioral measures. This is Grade A controlled human evidence that exogenous kisspeptin has direct effects on sexual and emotional brain processing in humans.
The HSDD clinical trials (Thurston 2022 and Mills 2023, both JAMA Network Open) translated the Comninos 2017 mechanistic findings into clinical application. In men with HSDD (clinically significant low sexual desire causing distress): Mills 2023 showed kisspeptin infusion significantly increased penile tumescence in response to erotic visual stimuli and enhanced sexual brain processing by fMRI — effects that did not occur in the placebo condition. The magnitude of penile tumescence response was clinically meaningful. In women with HSDD: Thurston 2022 showed kisspeptin increased self-reported sexual attraction to partner and altered brain responses to partner-specific bonding images. Both trials used IV infusion protocols not directly replicable by community SubQ use — but they establish that kisspeptin's behavioral effects are pharmacologically accessible, dose-dependent, and clinically relevant.
For the C4 audit: kisspeptin's behavioral pharmacology is pro-sexual and pro-bonding rather than dysphoric or concerning from an escalation/abuse potential perspective. No psychoactive effects independent of reproductive context have been documented. No euphoria, no reward pathway activation in the conventional drug-reinforcement sense, no habituation or craving. The behavioral effects are reproductively contextualized — kisspeptin amplifies sexual and bonding brain responses to relevant stimuli rather than creating non-specific drive or compulsive behavior. The safety profile from behavioral pharmacology is favorable. Potential concern: in individuals with sexual dysfunction secondary to hypogonadism or other causes, kisspeptin-enhanced sexual motivation without adequate resolution of the underlying cause could create motivational states without capacity for expression — but this is speculative.
Kisspeptin-10 and KP-54 have been administered in multiple human clinical trials with a consistently favorable safety profile. Documented adverse effects: mild transient facial flushing — the most commonly reported side effect; consistent with vasodilatory effects of KISS1R signaling; typically mild and self-limiting within minutes of injection. Mild headache — occasional; likely related to hypothalamic neurochemical effects; transient. Injection site reactions — typical for SubQ protein injection. No serious adverse events attributable to kisspeptin have been reported in published clinical trials. No HPTA suppression (the compound stimulates, not suppresses, the HPG axis when used correctly). No hepatotoxicity, nephrotoxicity, or organ toxicity documented. No WADA listed — kisspeptin is not on the WADA prohibited list (though the downstream testosterone elevation could theoretically raise testing flags; see Section 7.3).
The most important safety principle in kisspeptin administration — reviewed in the callout in Section 3.3 — is that continuous or too-frequent dosing produces paradoxical HPG axis suppression rather than stimulation. The practical dosing safety requirement: each injection must be separated by adequate time for KISS1R receptor resensitization. Based on receptor biology and clinical pharmacology data, a minimum 60-90 minute interval is needed before KISS1R can respond again; practical community protocols use 8-12+ hour intervals between doses. Evidence that suppression is occurring: falling LH and testosterone despite continued kisspeptin use; this would indicate KISS1R desensitization and requires discontinuation followed by washout.
Kisspeptin is not explicitly listed on the WADA Prohibited List as of 2025-2026. However, the testosterone elevation produced by kisspeptin stimulation could theoretically be detected as elevated endogenous testosterone (T:E ratio) in drug testing. Additionally, kisspeptin's mechanism of action — stimulating endogenous testosterone production — places it in conceptual proximity to other HPG axis-stimulating substances that are prohibited. For competitive athletes: the explicit absence from the WADA list means kisspeptin itself is not prohibited; but downstream testosterone effects require awareness. If kisspeptin is used in a PCT context following a period of exogenous testosterone use, the overall testing context is already concerning regardless of kisspeptin specifically.
Context
Form
Dose
Frequency
Route
Notes
Clinical trial (LH stimulation)
KP-10 or KP-54
Bolus: 0.3-1.0 nmol/kg IV; infusion: 0.01-0.1 nmol/kg/min IV
Single bolus or defined infusion period
IV
IV protocols not community-replicable; SubQ pharmacokinetics differ
IVF trigger (clinical)
KP-54
9.6 nmol/kg SubQ (Abbara 2015 dose)
Single injection 36h before oocyte retrieval
SubQ
FDA/EMA not approved; specialized fertility clinic use
Hypothalamic amenorrhea (clinical)
KP-10 or KP-54
SubQ pulses per published protocol
Every 90 minutes (pulsatile)
SubQ
Physician-supervised; pulsatile pump required for this protocol
Community PCT / testosterone support
KP-10
25-75 mcg per injection (community reference)
1-2x/day with 8-12+ hour minimum interval; never more frequent
SubQ
No controlled evidence; pulsatile principle mandatory; experimental
Community libido enhancement
KP-10
25-50 mcg per injection
1x/day or every other day
SubQ
No controlled evidence at community doses; behavioral effects at clinical doses were IV infusion
Kisspeptin is almost exclusively used in combination with other HPG-modulating compounds in the community context rather than as a standalone. The most common stacking configurations: (1) Kisspeptin + hCG: the most logical PCT combination. hCG directly stimulates Leydig cell testosterone production (testicular level); kisspeptin stimulates hypothalamic GnRH neuron activity (hypothalamic level). These act at different levels of the HPG axis and are not redundant. The hypothalamic signal (kisspeptin) and the testicular signal (hCG) should ideally be present simultaneously in PCT to provide the maximal synchronized top-to-bottom axis restart signal. Timing within PCT: kisspeptin during hCG phase or as Phase 0 before SERMs. (2) Kisspeptin + Gonadorelin: addresses hypothalamic and pituitary levels simultaneously. Gonadorelin (GnRH) bypasses kisspeptin-GnRH neuron signaling and directly stimulates pituitary LH secretion. In theory this provides dual coverage: kisspeptin reactivates hypothalamic GnRH neurons; gonadorelin provides direct pituitary stimulus. Experimental; no comparative evidence. (3) Kisspeptin + SERM: the standard PCT SERM phase (clomiphene, tamoxifen) blocks pituitary estrogen receptor suppression and allows LH recovery. Kisspeptin provides the upstream GnRH neuron signal that SERMs need to work with effectively. Adding kisspeptin to SERM therapy provides the hypothalamic component that SERMs alone cannot address. (4) Kisspeptin standalone: less common in PCT context; some community members use KP-10 for libido and testosterone support in non-PCT contexts, particularly during TRT bridges or in stress-related secondary hypogonadism cases.
Community observational experience with kisspeptin-10 in PCT contexts — compiled from practitioner reports and community forums with the appropriate Grade E caveat — shows several consistent themes: (1) Perceived faster HPG recovery when kisspeptin is added to standard PCT protocols; subjective testosterone-related symptoms (energy, libido, mood) return faster. (2) Significant variation in individual response — some users report robust LH and testosterone stimulation from 25-50 mcg SubQ doses; others report minimal effect. This variation may reflect differences in degree of hypothalamic KNDy neuron suppression, individual KP-10 bioavailability, or residual endogenous kisspeptin function. (3) The behavioral effects (libido enhancement, improved sexual motivation) are among the most consistently reported community observations — consistent with the Comninos 2017 limbic mechanism. (4) Facial flushing within minutes of injection is widely reported; consistent with clinical trial adverse event documentation. (5) Users who administered kisspeptin too frequently (multiple doses within a few hours) occasionally reported paradoxical worsening of symptoms — consistent with tachyphylaxis. This community observation is pharmacologically coherent and important for dosing guidance.
False at the receptor level. KP-10 and KP-54 have equal KISS1R binding affinity in vitro. The clinical difference is pharmacokinetic: KP-54's longer half-life (~28 min IV) produces a more sustained LH response after a single bolus compared to KP-10's (~4 min IV) more transient spike. This makes KP-54 more suitable for protocols requiring prolonged stimulation (IVF trigger) and KP-10 more suitable for pulsatile protocols requiring precise timing. For SubQ administration, the difference in effective half-life narrows and both are used effectively in community protocols.
Kisspeptin is not in the same category as tribulus, fenugreek, or ashwagandha. It is an injectable neuropeptide that directly activates the hypothalamic GnRH pulse generator. The testosterone elevation from kisspeptin is mediated through the same HPG cascade as physiological testosterone regulation — KISS1R → GnRH → LH → Leydig cells. This is pharmacologically categorically different from any oral supplement. The injection barrier, dose-sensitivity (continuous dosing suppresses rather than stimulates), and potential for meaningful hormonal perturbation place kisspeptin firmly in the pharmaceutical/research chemical category, not the supplement category.
This is the most dangerous misconception in kisspeptin use. Frequent administration without adequate KISS1R resensitization intervals produces paradoxical suppression of the HPG axis — potentially causing hypogonadism. The receptor biology is clear: continuous KISS1R agonism desensitizes GnRH neurons and collapses GnRH pulsatility. Community protocols using KP-10 multiple times per day with short intervals risk axis suppression. The minimum interval between doses is 8-12 hours; some practitioners recommend every-other-day dosing to ensure complete receptor resensitization.
Kisspeptin has been validated in clinical research for reproductive endocrinology indications — specifically HH, hypothalamic amenorrhea, and IVF triggering. It has not been studied in post-AAS PCT specifically. The mechanistic case for kisspeptin in PCT is genuinely compelling; the controlled trial evidence does not exist. Treating kisspeptin as PCT-validated conflates its reproductive endocrinology evidence base with the specific AAS-PCT context where different pharmacological factors apply (AAS-specific receptor suppression patterns, interaction with hCG and SERMs, timing relative to AAS clearance).
Historical accuracy: KISS1 was discovered as a metastasis suppressor gene. It was named after Hershey's Kisses in Pennsylvania. It was not initially known to have reproductive significance. The reproductive function was discovered 5 years later. The kisspeptin name was coined post-discovery of the reproductive role. This origin story illustrates how unexpected the compound's pharmacological importance in reproduction turned out to be — reinforcing the principle that the most clinically important molecules are often found doing something unexpected.
Gonadorelin is synthetic GnRH — it acts one step downstream of kisspeptin, directly on pituitary GnRH receptors rather than on hypothalamic GnRH neurons. Both can stimulate LH and testosterone. The mechanistic difference matters for specific applications: Gonadorelin bypasses the hypothalamus entirely and directly stimulates the pituitary gonadotroph cells. Kisspeptin activates the hypothalamic GnRH neurons and requires an intact GnRH neuron-pituitary pathway to produce LH. In men with a suppressed hypothalamic GnRH pulse generator but intact pituitary: gonadorelin can directly stimulate LH even when the hypothalamus is silent; kisspeptin cannot (because it works through the hypothalamic neurons). In men with an intact hypothalamus but suppressed KNDy neuron activity (the post-AAS scenario where androgens have suppressed KISS1 expression): kisspeptin may activate dormant KNDy neurons and GnRH neurons that still have KISS1R; gonadorelin can simultaneously support the pituitary directly. Some advanced PCT practitioners combine both — kisspeptin (hypothalamic level) and gonadorelin (pituitary level) — for a theoretically comprehensive HPG restart from both ends. This combination is experimental with no controlled evidence.
Beyond post-AAS PCT, kisspeptin has potential relevance in another form of HPG suppression that is common in performance and longevity communities: chronic stress-mediated hypothalamic suppression. Cortisol and CRH (corticotropin-releasing hormone) from chronic stress directly suppress KNDy neuron activity and KISS1 gene expression in the arcuate nucleus. This explains why extreme endurance athletes, individuals with caloric restriction or metabolic stress, and people experiencing chronic psychological stress often have secondary hypogonadism — low testosterone despite anatomically normal testes and pituitary. The same mechanism that causes hypothalamic amenorrhea in women occurs in men under severe physiological or psychological stress. Kisspeptin's role in addressing this specific form of hypogonadism — where the problem is at the hypothalamic kisspeptin neuron level rather than the pituitary or testicular level — is an emerging clinical concept. The hypothalamic amenorrhea evidence (where stress and metabolic suppression of KNDy neurons is restored by exogenous kisspeptin) provides the closest clinical parallel for men with stress-related secondary hypogonadism.
A broader gap: the entire field of community kisspeptin use is essentially running ahead of the clinical evidence base. The reproductive endocrinology evidence is strong and well-characterized — hypothalamic amenorrhea, IVF triggering, HH diagnostic testing are all Grade A or B. Community use extends this evidence into PCT, general testosterone support, stress-related hypogonadism, and libido enhancement — none of which have controlled trials. The pharmacological reasoning is sound; the clinical evidence has not caught up. This is not unusual in the peptide community, but the specific tachyphylaxis risk makes kisspeptin more dangerous to use incorrectly than most other compounds where the worst case from overdosing is reduced efficacy rather than paradoxical suppression.
Seminara SB, Messager S, Chatzidaki EE et al. (2003). The GPR54 gene as a regulator of puberty. New England Journal of Medicine. 349:1614-1627. [Landmark 2003 paper; GPR54 loss-of-function causes HH; establishes kisspeptin/KISS1R as obligatory for puberty and reproduction.]
de Roux N, Genin E, Carel JC, Matsuda F, Chaussain JL, Milgrom E. (2003). Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proceedings of the National Academy of Sciences USA. 100(19):10972-10976. [Simultaneous 2003 landmark paper; same conclusion reached independently.]
George JT, Veldhuis JD, Roseweir AK, Anderson RA, McNeilly AS, Millar RP, Bhattacharya S. (2011). Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. Journal of Clinical Endocrinology and Metabolism. 96(8):E1228-1236. [The foundational KP-10 human study; 2.5x LH increase; pulse frequency increase; abolished by GnRH antagonist; establishes KP-10 clinical pharmacology.]
Comninos AN, Wall MB, Demetriou L et al. (2017). Kisspeptin modulates sexual and emotional brain processing in humans. Journal of Clinical Investigation. 127(2):709-719. PMC5272173. [The foundational limbic fMRI study; 29 healthy men; kisspeptin enhances limbic response to sexual/bonding stimuli; correlated with behavioral measures; Grade A evidence for limbic effects.]
Mills EG, Bhatt D, Comninos AN et al. (2023). Effects of kisspeptin on sexual brain processing and penile tumescence in men with hypoactive sexual desire disorder: a randomized clinical trial. JAMA Network Open. 6:e2254313. [RCT in men with HSDD; kisspeptin improved penile tumescence and sexual brain processing; Phase 2 RCT evidence for HSDD application.]
Thurston L, Comninos AN, George JT et al. (2022). Effects of kisspeptin administration in women with hypoactive sexual desire disorder: a randomized clinical trial. JAMA Network Open. 5:e2236131. [RCT in women with HSDD; kisspeptin increased sexual attraction to partner; Phase 2 RCT evidence.]
Jayasena CN, Abbara A, Comninos AN et al. Multiple published RCTs 2014-2018. Pulsatile kisspeptin administration restores LH pulsatility and induces ovulation in women with hypothalamic amenorrhea; kisspeptin-54 as IVF trigger with reduced OHSS risk. [Multiple papers from Imperial College London group; Grade A evidence for reproductive endocrinology applications.]
Kisspeptin-10 is perhaps the most pharmacologically sophisticated compound in the community PCT toolkit — and the one whose evidence base, while impressive for reproductive endocrinology, most clearly does not yet extend to the community's primary use case.
The central tension resolved: the evidence for kisspeptin in its studied clinical contexts is genuinely strong. Pulsatile kisspeptin restores GnRH pulsatility in hypothalamic amenorrhea. KP-10 stimulates LH in healthy men. KISS1R signaling is obligatory for human puberty and reproduction. The Comninos 2017 fMRI data shows kisspeptin enhances limbic brain processing of sexual and bonding stimuli. The HSDD RCTs show clinical improvements in sexual function. None of this evidence was generated in the post-AAS PCT context. The community PCT application is mechanistically compelling — kisspeptin addresses the hypothalamic level that hCG and SERMs don't — but it remains experimental, without a controlled trial to guide optimal dosing, timing, or combination.
The tachyphylaxis principle is the most clinically critical pharmacology in this chapter: kisspeptin used incorrectly (too frequently) produces axis suppression, not stimulation. This is not a minor dosing nuance; it is a safety-critical pharmacological property that makes kisspeptin qualitatively different from most compounds in this book. Doses that are too frequent can produce hypogonadism. Pulsatile dosing with adequate intervals is not optional.
Every person using kisspeptin must internalize one concept before the first injection: pulsatile = stimulation; continuous = suppression. This is not a general principle about 'taking breaks.' It is a receptor biology phenomenon where wrong dosing frequency produces pharmacological castration. Minimum 8-12 hour intervals between doses. Never dose more than twice daily. If testosterone or LH appears to be falling during kisspeptin use, stop immediately and allow washout.
— End of Kisspeptin-10 —
THE PEPTIDE BIBLE | Kisspeptin-10 | For Research & Educational Purposes Only
Kisspeptin-10 (KP-10): 10 C-terminal amino acids of kisspeptin-54. Sequence: Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂. C-terminal amidation essential. MW ~1302 Da. Encoded by KISS1 gene — named after Hershey's Kisses, Pennsylvania, where it was discovered as a metastasis suppressor gene in 1996. Reproductive function discovered 2001-2003. KISS1R (GPR54) loss-of-function mutations cause hypogonadotropic hypogonadism — proving the pathway is obligatory for human puberty and reproduction (Seminara 2003 NEJM; de Roux 2003). THE HPG APEX: KNDy neurons (Kisspeptin/Neurokinin B/Dynorphin) in hypothalamic arcuate nucleus are the GnRH pulse generator. KP-10 binding KISS1R (Gq/11-coupled) on GnRH neurons → PLC → IP3 → Ca²⁺ → GnRH secretion → LH/FSH → testosterone. KISS1R also expressed in amygdala, hippocampus, limbic structures. TACHYPHYLAXIS: THE CRITICAL SAFETY ISSUE — continuous KISS1R agonism → receptor desensitization/internalization → GnRH neurons unresponsive → HPG suppression (same mechanism as GnRH agonist medical castration). Pulsatile dosing is mandatory — minimum 8-12 hour intervals between doses. Too-frequent dosing = paradoxical hypogonadism. KP-10 vs KP-54: equal KISS1R affinity/potency; KP-10 shorter half-life (~4 min IV) = better for pulsatile; KP-54 longer (~28 min IV) = better for sustained stimulation (IVF trigger). EVIDENCE: LH stimulation in healthy men (A — George 2011 JCEM, 2.5x LH increase); hypothalamic amenorrhea (A — Jayasena et al. multiple RCTs); IVF trigger (A — Abbara 2015 and follow-up RCTs, reduced OHSS); HH diagnostic probe (A); HSDD women (B — Thurston 2022 JAMA Netw Open); HSDD men (B — Mills 2023 JAMA Netw Open); limbic brain sexual/bonding processing (A — Comninos 2017 JCI fMRI); PCT post-AAS (D-E — no controlled trial, mechanistically compelling). BEHAVIORAL: KISS1R in amygdala/hippocampus amplifies limbic response to sexual/bonding stimuli (Comninos 2017); enhanced drive, reward sensitivity, reduced sexual aversion; no euphoria/escalation risk; pro-reproductive behavioral profile. DOSING (COMMUNITY): 25-75 mcg KP-10 SubQ; 1-2x/day maximum; 8-12+ hour minimum interval; pulsatile mandatory; experimental for PCT use. SAFETY: facial flushing (most common); no serious AEs in clinical trials; no HPTA suppression when dosed correctly; no WADA listing (but downstream testosterone effects require awareness). WADA: not currently prohibited.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.